IMR Press / FBL / Volume 11 / Issue 2 / DOI: 10.2741/1936

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Laboratory analysis of T-cell immunity
Show Less
1 Department of Immunology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
2 Tumor Vaccine Group University of Washington Center for Translational Medicine in Women’s Health, Seattle, WA 98195
Front. Biosci. (Landmark Ed) 2006, 11(2), 1932–1944;
Published: 1 May 2006

Immune-based strategies for treating and preventing cancer are increasingly being tested and include cancer vaccination, adoptive T cell therapy, and cytokine therapy. An important component of testing and development of immune-based strategies is monitoring the immunologic response. The ability to monitor T cell immunity has been suboptimal. The measurement of tumor-specific immunity will aid in defining which strategies should be moved forward in clinical trials and which should be eliminated or evaluated further in the preclinical realm. Immunologic monitoring is necessary for determining if an approach has immunologic efficacy and ultimately whether immunologic responses correlate with a clinical response. This article discusses several important elements of measuring T cell immunity such as validation principles, laboratory issues, current approaches, and new paradigms and concepts for future testing. Informative immunologic monitoring of T cells will be one of the driving forces in advancing the field of tumor immunology.

T cell
cytokine flow cytometry
CD4 T cell
CD8 T cell
Back to top